SCHEMBL333827

SCHEMBL333827

C=CCC(O)C(C)C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14423728 1.00
Isobutyraldehyde SCHEMBL10396298 0.88
SCHEMBL13497243 0.82
SCHEMBL5471232 0.82
SCHEMBL7055847 0.81 TSHR (0.38)
SCHEMBL27620410 0.80
SCHEMBL28740652 0.79 CYP3A4 (0.33)
SCHEMBL6063925 0.78
SCHEMBL20209660 0.78
SCHEMBL11941616 0.76

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105461634-A Preparation method of enzalutamide JIANGSU HANSOH PHARMACEUTICAL GROUP LIANYUNGANG HONGCHUANG PHARMACEUTICAL CO LTD 2016-04-06 CN claimed
US-4474980-A Process for the preparation of intermediates for pyrethroids MONTEDISON S.P.A. (IT) 1984-10-02 US claimed
US-20250179091-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMA (US) 2025-06-05 US disclosed
EP-4192829-B1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMA (US) 2025-05-07 EP disclosed
US-12269831-B2 Modulators of cystic fibrosis transmembrane conductance regulator VERTEX PHARMACEUTICALS INCORPORATED (US) 2025-04-08 US disclosed
EP-4192829-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR Vertex Pharmaceuticals Incorporated (US) 2023-06-14 EP disclosed
CN-116171154-A Modulators of cystic fibrosis transmembrane conductance regulator 弗特克斯药品有限公司 2023-05-26 CN disclosed
CN-108349960-B Nostoc compounds and conjugates, their preparation and their therapeutic use 赛诺菲 2022-05-27 CN disclosed
US-20220041621-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED 2022-02-10 US disclosed
WO-2022032068-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS INCORPORATED (US) 2022-02-10 WO disclosed
US-11033556-B2 Bicyclic sulfonamides ALIGOS THERAPEUTICS, INC. (US) 2021-06-15 US disclosed
EP-1985620-A1 10a-AZALIDE COMPOUND TAISHO PHARMACEUTICAL CO., LTD (JP) 2008-10-29 EP disclosed
EP-1948712-A2 IONIZING RADIATION STABLE THERMOPLASTIC COMPOSITION, METHOD OF MAKING, AND ARTICLES FORMED THEREFROM General Electric Company (US) 2008-07-30 EP disclosed
WO-2007061672-A2 IONIZING RADIATION STABLE THERMOPLASTIC COMPOSITION, METHOD OF MAKING, AND ARTICLES FORMED THEREFROM GENERAL ELECTRIC COMPANY (US) 2007-05-31 WO disclosed
US-6989392-B2 2-Aminoquinolines as melanin concentrating hormone receptor antagonists ABBOTT LABORATORIES (US) 2006-01-24 US disclosed
US-20040063756-A1 2-Aminoquinolines as melanin concentrating hormone receptor antagonists ABBVIE INC. 2004-04-01 US disclosed
WO-2003105850-A1 2-AMINOQUINOLINES AS MELANIN CONCENTRATING HORMONE RECEPTOR ANTAGONISTS ABBOTT LABORATORIES (US) 2003-12-24 WO disclosed
CN-1204328-A 1, 3-oxazin-4-one derivatives as herbicides RHONE POULENC AGRICULTURE (GB) 1999-01-06 CN disclosed
US-4474980-A Process for the preparation of intermediates for pyrethroids MONTEDISON S.P.A. (IT) 1984-10-02 US disclosed
US-4111917-A POLYURETHANES W. R. GRACE & CO. (US) 1978-09-05 US disclosed